{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:51:20Z","timestamp":1788871880442,"version":"build-2803163510"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T00:00:00Z","timestamp":1400803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CR-UK","award":["A11008"],"award-info":[{"award-number":["A11008"]}]},{"name":"CR-UK","award":["C596\/A17196"],"award-info":[{"award-number":["C596\/A17196"]}]},{"name":"CR-UK","award":["101703\/Z\/13\/Z"],"award-info":[{"award-number":["101703\/Z\/13\/Z"]}]},{"name":"CR-UK","award":["F217"],"award-info":[{"award-number":["F217"]}]},{"name":"CR-UK","award":["6\/29\/1"],"award-info":[{"award-number":["6\/29\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogene addiction describes the dependence of some cancers on one or a few genes for their survival. Inhibition of the corresponding oncoproteins can lead to dramatic responses. However, in some cases, such as chronic myeloid leukemia (CML), a disease characterized by the presence of the abnormal fusion tyrosine kinase BCR-ABL, cancer stem cells may never acquire addiction to the oncogene that drives disease development. The suggested mechanism(s) for treatment failure include a quiescent stem cell population capable of reinstating disease, high levels of oncoprotein expression, or acquired mutations in the oncogene. In this review, we discuss the evidence for oncogene addiction in several solid tumors and their potential escape mechanism(s) with a particular focus on CML stem cells. Stem Cells \u00a02014;32:1373\u20131379<\/jats:p>","DOI":"10.1002\/stem.1678","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T06:59:54Z","timestamp":1392188394000},"page":"1373-1379","source":"Crossref","is-referenced-by-count":25,"title":["Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting"],"prefix":"10.1093","volume":"32","author":[{"given":"Francesca","family":"Pellicano","sequence":"first","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre Institute of Cancer Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,5,23]]},"reference":[{"key":"2022011201125740400_stem1678-bib-0001","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","article-title":"Oncogene addiction","volume":"68","author":"Weinstein","year":"2008","journal-title":"Cancer Res"},{"key":"2022011201125740400_stem1678-bib-0002","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/carcin\/21.5.857","article-title":"Disorders in cell circuitry during multistage carcinogenesis: The role of homeostasis","volume":"21","author":"Weinstein","year":"2000","journal-title":"Carcinogenesis"},{"issue":"pt 2","key":"2022011201125740400_stem1678-bib-0003","first-page":"2696","article-title":"Disorders in cell circuitry associated with multistage carcinogenesis: Exploitable targets for cancer prevention and therapy","volume":"3","author":"Weinstein","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2022011201125740400_stem1678-bib-0004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/emmm.201100176","article-title":"Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: Promises and perils","volume":"3","author":"Torti","year":"2011","journal-title":"EMBO Mol Med"},{"key":"2022011201125740400_stem1678-bib-0005","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022011201125740400_stem1678-bib-0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2147\/TCRM.S1526","article-title":"Treatment of gastrointestinal stromal tumor: Focus on imatinib mesylate","volume":"4","author":"Din","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2022011201125740400_stem1678-bib-0007","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0008","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2022011201125740400_stem1678-bib-0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"2022011201125740400_stem1678-bib-0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann Oncol"},{"key":"2022011201125740400_stem1678-bib-0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.med.59.090506.202405","article-title":"EGFR tyrosine kinase inhibitors in lung cancer: An evolving story","volume":"59","author":"Sequist","year":"2008","journal-title":"Annu Rev Med"},{"key":"2022011201125740400_stem1678-bib-0012","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022011201125740400_stem1678-bib-0013","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: Preclinical data and clinical implications","volume":"13","author":"Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022011201125740400_stem1678-bib-0014","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0015","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.coph.2008.06.016","article-title":"Targeted therapy for cancer using PARP inhibitors","volume":"8","author":"Lord","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"2022011201125740400_stem1678-bib-0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa1011418","article-title":"Iniparib plus chemotherapy in metastatic triple-negative breast cancer","volume":"364","author":"O\u2019Shaughnessy","year":"2011","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0019","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1101\/gad.1609907","article-title":"Oncogene addiction: Setting the stage for molecularly targeted cancer therapy","volume":"21","author":"Sharma","year":"2007","journal-title":"Genes Dev"},{"key":"2022011201125740400_stem1678-bib-0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"2022011201125740400_stem1678-bib-0021","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0023","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"2022011201125740400_stem1678-bib-0024","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0025","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0026","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"key":"2022011201125740400_stem1678-bib-0027","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0028","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0029","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2022011201125740400_stem1678-bib-0030","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"2022011201125740400_stem1678-bib-0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat Genet"},{"key":"2022011201125740400_stem1678-bib-0032","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0033","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1182\/blood-2009-04-215376","article-title":"BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells","volume":"115","author":"Schemionek","year":"2010","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0034","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/emboj.2008.253","article-title":"Cancer induction by restriction of oncogene expression to the stem cell compartment","volume":"28","author":"Perez-Caro","year":"2009","journal-title":"Embo J"},{"key":"2022011201125740400_stem1678-bib-0035","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2011","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0036","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"2022011201125740400_stem1678-bib-0037","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0038","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistency in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0039","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"2022011201125740400_stem1678-bib-0040","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation","volume":"90","author":"Merante","year":"2005","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2022011201125740400_stem1678-bib-0041","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission","volume":"28","author":"Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"2022011201125740400_stem1678-bib-0042","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years","volume":"118","author":"Su Chu","year":"2011","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0043","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022011201125740400_stem1678-bib-0044","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0045","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2022011201125740400_stem1678-bib-0046","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"2022011201125740400_stem1678-bib-0047","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Pellicano","year":"2011","journal-title":"J Exp Med"},{"key":"2022011201125740400_stem1678-bib-0048","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"key":"2022011201125740400_stem1678-bib-0049","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829.422k14_3829_3840","article-title":"Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia","volume":"92","author":"Zhang","year":"1998","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0050","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1128\/MCB.19.10.6918","article-title":"Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy","volume":"19","author":"Gross","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2022011201125740400_stem1678-bib-0051","doi-asserted-by":"crossref","first-page":"e7439","DOI":"10.1371\/journal.pone.0007439","article-title":"A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice","volume":"4","author":"Johnson","year":"2009","journal-title":"PLoS One"},{"key":"2022011201125740400_stem1678-bib-0052","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jnci\/djt006","article-title":"Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex","volume":"105","author":"Chen","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2022011201125740400_stem1678-bib-0053","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/ng.389","article-title":"Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia","volume":"41","author":"Chen","year":"2009","journal-title":"Nat Genet"},{"key":"2022011201125740400_stem1678-bib-0054","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"key":"2022011201125740400_stem1678-bib-0055","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/blood-2009-05-219550","article-title":"BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem\/progenitor cells, including CD34+38\u2212 cells, through activation of protein kinase Cbeta","volume":"114","author":"Pellicano","year":"2009","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0056","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"2022011201125740400_stem1678-bib-0057","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"2022011201125740400_stem1678-bib-0058","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"2022011201125740400_stem1678-bib-0059","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"Kumari","year":"2012","journal-title":"Blood"},{"key":"2022011201125740400_stem1678-bib-0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11899-012-0152-z","article-title":"Role of epigenetics in chronic myeloid leukemia","volume":"8","author":"Machova Polakova","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"2022011201125740400_stem1678-bib-0061","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"2022011201125740400_stem1678-bib-0062","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.stem.2012.05.024","article-title":"Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells","volume":"11","author":"Ashton","year":"2012","journal-title":"Cell Stem Cell"},{"key":"2022011201125740400_stem1678-bib-0063","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nature06973","article-title":"Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype","volume":"453","author":"McMurray","year":"2008","journal-title":"Nature"},{"key":"2022011201125740400_stem1678-bib-0064","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat Rev Cancer"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.1678","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.1678","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.1678","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/6\/1373\/41983635\/stmcls_32_6_1373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/6\/1373\/41983635\/stmcls_32_6_1373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T21:52:32Z","timestamp":1642542752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/32\/6\/1373-1379\/6444483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,23]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,23]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.1678","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,6,1]]},"published":{"date-parts":[[2014,5,23]]}}}